• 1
    Briasoulis A, Tousoulis D, Antoniades C, et al. The oxidative stress menace to coronary vasculature: any place for antioxidants? Curr Pharm Des 2009; 15: 30783090.
  • 2
    Victor VM, Rocha M, Solá E, et al. Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 2009; 15: 29883002.
  • 3
    Yamagishi S, Nakamura K, Matsui T. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr Med Chem 2008; 15: 172177.
  • 4
    Antonopoulos AS, Antoniades C, Tousoulis D, et al. Novel therapeutic strategies targeting vascular redox in human atherosclerosis. Recent Pat Cardiovasc Drug Discov 2009; 4: 7687.
  • 5
    Francia P, Cosentino F, Schiavoni M, et al. p66(Shc) protein, oxidative stress, and cardiovascular complications of diabetes: the missing link. J Mol Med 2009; 87: 885891.
  • 6
    Pellegrini M, Baldari CT. Apoptosis and oxidative stress-related diseases: the p66Shc connection. Curr Mol Med 2009; 9: 392398.
  • 7
    Francia P, delli Gatti C, Bachschmid M, et al. Deletion of p66shc gene protects against age-related endothelial dysfunction. Circulation 2004; 110: 28892895.
  • 8
    Napoli C, Martin-Padura I, de Nigris F, et al. Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet. Proc Natl Acad Sci U S A 2003; 100: 21122116.
  • 9
    Martin-Padura I, de Nigris F, Migliaccio E, et al. p66Shc deletion confers vascular protection in advanced atherosclerosis in hypercholesterolemic apolipoprotein E knockout mice. Endothelium 2008; 15: 276287.
  • 10
    Tahara N, Kai H, Yamagishi S, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 2007; 49: 15331539.
  • 11
    Imai E, Horio M, Nitta K, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 4150.
  • 12
    Miura J, Uchigata Y, Yamamoto Y, et al. AGE down-regulation of monocyte RAGE expression and its association with diabetic complications in type 1 diabetes. J Diabetes Complications 2004; 18: 5359.
  • 13
    Wilson HM, Barker RN, Erwig LP. Macrophages: promising targets for the treatment of atherosclerosis. Curr Vasc Pharmacol 2009; 7: 234243.
  • 14
    Saha P, Modarai B, Humphries J, et al. The monocyte/macrophage as a therapeutic target in atherosclerosis. Curr Opin Pharmacol 2009; 9: 109118.
  • 15
    Pagnin E, Fadini G, de Toni R, Tiengo A, Calò L, Avogaro A. Diabetes induces p66shc gene expression in human peripheral blood mononuclear cells: relationship to oxidative stress. J Clin Endocrinol Metab 2005; 90: 11301136.